The FDA has responded to concerns about the impact on clinical trials of the novel coronavirus with guidance on how to modify trial designs to mitigate the impact of the COVID-19 crisis.
Researchers rely on a steady stream of volunteers to test and validate their products – yet clinical trial recruitment and retention are significant barriers to success.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.